Gastroparesis Trial Launched to Test New Oral Therapy
A new clinical trial will investigate if an oral medication can address the underlying causes of delayed gastric emptying.
Updated on Sept. 24, 2026 in Diabetes
Live Poll
Do you believe pharmaceutical companies are doing enough to develop treatments for rare chronic diseases?
Aclipse Therapeutics has signed a research agreement with the Mayo Clinic to launch a Phase 2 clinical trial, known as LOGAST, for the investigational drug M107. The study aims to evaluate this treatment for patients with idiopathic gastroparesis, a condition that disrupts the normal movement of food from the stomach to the small intestine.
Why it matters
Currently, there are no approved medications that fundamentally address the underlying causes of gastroparesis. This clinical trial seeks to determine if a novel approach can offer a more effective management strategy for this challenging disorder.
The LOGAST trial is a Phase 2 study conducted across three Mayo Clinic campuses designed to evaluate M107 for idiopathic gastroparesis. While the study is in its planning stages, researchers will test the drug's impact on a condition for which no fundamental treatments currently exist.
The players
Aclipse Therapeutics
A biopharmaceutical company partnering on global clinical research for novel therapeutic candidates.
Mayo Clinic
A prominent non-profit medical center that provides clinical care and leads advanced medical research studies.
CKD
A South Korea-based pharmaceutical firm specializing in research and development of medical treatments.
The details
The experimental drug M107 is based on the active ingredient lobeglitazone. It is designed to work by promoting the expression of anti-inflammatory M2 macrophages while reducing pro-inflammatory M1 macrophages. By modulating these immune responses in the stomach, the treatment aims to correct the delayed gastric emptying characteristic of the disease.
Timeline
CKD and Aclipse signed a global licensing agreement in 2023.
Patient enrollment for the clinical trial is expected to begin in the first quarter of 2026.
Health Landscape
The LOGAST trial utilizes the Mayo Clinic clinical research infrastructure to move M107 from a licensing agreement into human testing. This study represents a departure from current symptomatic management, aiming to address the disease at the cellular level.
Gastroparesis causes chronic delayed stomach emptying, which often complicates blood sugar control for those also living with diabetes. If you have been diagnosed with this condition, discuss the ongoing status of clinical research with your gastroenterologist to stay informed about potential future options.
The takeaway
While currently in the testing phase, this research represents an effort to identify the first therapy that targets the biological mechanisms of gastroparesis. Patients should monitor official clinical trial registries to track the progress of new treatment candidates.
What happens next
Patient enrollment for the LOGAST trial is scheduled to begin in the first quarter of 2026.
Further reading
Learn more about the latest research and management strategies for this condition in our Diabetes section.
Source note: This article includes information reported by Pulse.
Live Poll
Do you believe pharmaceutical companies are doing enough to develop treatments for rare chronic diseases?
